BG105339A - Orally administered controlled drug delivery system providing temporal and spatial control - Google Patents

Orally administered controlled drug delivery system providing temporal and spatial control

Info

Publication number
BG105339A
BG105339A BG105339A BG10533901A BG105339A BG 105339 A BG105339 A BG 105339A BG 105339 A BG105339 A BG 105339A BG 10533901 A BG10533901 A BG 10533901A BG 105339 A BG105339 A BG 105339A
Authority
BG
Bulgaria
Prior art keywords
drug
drug delivery
temporal
spatial control
capsule
Prior art date
Application number
BG105339A
Other languages
Bulgarian (bg)
English (en)
Inventor
Naresh Talwar
Hinadri SEN
John Staniforth
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of BG105339A publication Critical patent/BG105339A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG105339A 1998-09-14 2001-03-13 Orally administered controlled drug delivery system providing temporal and spatial control BG105339A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control
PCT/IB1999/000078 WO2000015198A1 (en) 1998-09-14 1999-01-19 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number Publication Date
BG105339A true BG105339A (en) 2001-11-30

Family

ID=22545063

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105339A BG105339A (en) 1998-09-14 2001-03-13 Orally administered controlled drug delivery system providing temporal and spatial control

Country Status (41)

Country Link
EP (2) EP1281397A1 (xx)
JP (1) JP2002524494A (xx)
CN (1) CN1186013C (xx)
AP (1) AP1659A (xx)
AR (1) AR022672A1 (xx)
AT (1) ATE245414T1 (xx)
AU (1) AU758324B2 (xx)
BG (1) BG105339A (xx)
BR (1) BR9913696A (xx)
CA (1) CA2343760A1 (xx)
CO (1) CO5130022A1 (xx)
CU (1) CU23040A3 (xx)
CZ (1) CZ2001901A3 (xx)
DE (1) DE69909801T2 (xx)
DK (1) DK1107741T3 (xx)
EA (2) EA005767B1 (xx)
EE (1) EE200100153A (xx)
ES (1) ES2204098T3 (xx)
GE (1) GEP20043216B (xx)
HK (1) HK1037967A1 (xx)
HR (1) HRP20010187B1 (xx)
HU (1) HUP0103632A3 (xx)
ID (1) ID29843A (xx)
IL (1) IL141977A0 (xx)
IS (1) IS5885A (xx)
MX (1) MXPA01002634A (xx)
MY (1) MY127952A (xx)
NO (1) NO20011276L (xx)
NZ (2) NZ510487A (xx)
OA (1) OA11652A (xx)
PE (1) PE20001058A1 (xx)
PL (1) PL346798A1 (xx)
PT (1) PT1107741E (xx)
SI (1) SI1107741T1 (xx)
SK (1) SK285478B6 (xx)
SV (1) SV1999000152A (xx)
TR (1) TR200100731T2 (xx)
UA (1) UA73287C2 (xx)
UY (1) UY25710A1 (xx)
WO (1) WO2000015198A1 (xx)
ZA (1) ZA995839B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400950A1 (en) * 2000-03-03 2001-09-07 Ranbaxy Laboratories Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6861071B2 (en) 2000-08-08 2005-03-01 Daiichi Pharmaceutical Co., Ltd. Highly absorptive solid preparation
IN192748B (xx) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
EP1347748A2 (en) * 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
WO2003015745A1 (en) * 2001-08-16 2003-02-27 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
AU2002351798A1 (en) * 2001-10-29 2003-05-12 Labopharm Inc. Methods and dosage forms for improving the bioavailability of therapeutic agents
CA2466657C (en) * 2001-11-13 2011-02-01 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
ES2259011T3 (es) 2001-11-19 2006-09-16 Lupin Limited Composicion farmaceutica para la liberacion controlada de un antibiotico beta-lactama.
SK285383B6 (sk) * 2002-04-23 2006-12-07 Lupin Limited Kompozície matrice s modifikovaným uvoľňovaním, sdlhodobým účinkom
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
AU2006263338A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
KR20110042366A (ko) 2008-08-18 2011-04-26 팀 아카데미 오브 파마슈티컬 사이언스 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
CN106999429B (zh) * 2014-11-19 2020-09-18 杜邦营养美国有限公司 纳米悬浮剂制剂
DK3648747T3 (da) 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP3824881B1 (en) 2018-06-18 2022-02-16 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
EP3628004B1 (en) 2018-06-27 2021-09-22 Amneal Complex Products Research LLC Self-regulating osmotic gastroretentive drug delivery systems
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
AU758324B2 (en) 2003-03-20
PT1107741E (pt) 2003-12-31
HRP20010187A2 (en) 2002-04-30
PL346798A1 (en) 2002-02-25
SI1107741T1 (en) 2004-02-29
AP2001002098A0 (en) 2001-03-31
BR9913696A (pt) 2001-10-09
DK1107741T3 (da) 2003-11-17
IL141977A0 (en) 2002-03-10
IS5885A (is) 2001-03-12
AP1659A (en) 2006-09-06
TR200100731T2 (tr) 2001-06-21
ES2204098T3 (es) 2004-04-16
HRP20010187B1 (en) 2004-04-30
NZ523747A (en) 2004-04-30
HUP0103632A3 (en) 2005-06-28
EP1281397A1 (en) 2003-02-05
AU1779499A (en) 2000-04-03
EE200100153A (et) 2002-06-17
ATE245414T1 (de) 2003-08-15
SK285478B6 (sk) 2007-02-01
EA004443B1 (ru) 2004-04-29
NZ510487A (en) 2003-04-29
DE69909801D1 (de) 2003-08-28
DE69909801T2 (de) 2004-06-03
NO20011276L (no) 2001-05-10
UY25710A1 (es) 2000-03-31
AR022672A1 (es) 2002-09-04
CA2343760A1 (en) 2000-03-23
HK1037967A1 (en) 2002-03-01
PE20001058A1 (es) 2000-10-05
WO2000015198A1 (en) 2000-03-23
JP2002524494A (ja) 2002-08-06
ID29843A (id) 2001-10-18
EP1107741B1 (en) 2003-07-23
NO20011276D0 (no) 2001-03-13
EA200300847A1 (ru) 2003-12-25
UA73287C2 (en) 2005-07-15
CN1325299A (zh) 2001-12-05
ZA995839B (en) 2000-03-28
SK3472001A3 (en) 2001-10-08
MY127952A (en) 2007-01-31
MXPA01002634A (es) 2002-06-04
CN1186013C (zh) 2005-01-26
CZ2001901A3 (cs) 2001-08-15
GEP20043216B (en) 2004-04-26
EP1107741A1 (en) 2001-06-20
EA005767B1 (ru) 2005-06-30
SV1999000152A (es) 2000-07-03
EA200100346A1 (ru) 2001-10-22
CO5130022A1 (es) 2002-02-27
OA11652A (en) 2004-12-08
CU23040A3 (es) 2005-04-14
HUP0103632A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
BG105339A (en) Orally administered controlled drug delivery system providing temporal and spatial control
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
EP1104288B1 (en) Orally disintegrable tablet forming a viscous slurry
CN100551377C (zh) 用于治疗和预防骨质疏松症的二膦酸
IL143375A0 (en) Sustained release matrix systems for highly soluble drugs
AU7143796A (en) Controlled release matrix for pharmaceuticals
NZ322053A (en) Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
PL304860A1 (en) Drug of prolonged active substance release containing a tramadol salt
KR20030023879A (ko) 알렌드로네이트 및/또는 기타 비스-포스포네이트의 지연형위 방출을 위한 조성물 및 제형
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
AP2002002410A0 (en) Hydrodynamically Balancing Oral Drug Delivery System
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
JP2776837B2 (ja) 消化性潰瘍治療剤
ECSP993138A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
DE60219965D1 (de) Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
TH50543A3 (th) ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ
TWI229609B (en) Pharmaceutical composition of orally administered controlled drug delivery system providing temporal and spatial control
EP1688131A1 (en) Orally disintegratable tablet forming a viscous slurry